DSIJ Mindshare

Hot Chips - Stock recommendations for your portfolio

INDRAPRASTHA GAS | BSE Code: 532514 | Volume: 245000 | CMP: Rs 359

After having hiked the price of CNG by Rs 1.75/kg at the end of December 2011, Indraprastha Gas (IGL) has announced another hike of Rs 1.70/kg, taking the CNG prices in Delhi to Rs 35.45/kg. The price hike will provide a significant boost to IGL’s profitability going forward. This hike and the consequent improved profitability will help the company in meeting its FY12 projections. The hike in prices will act as a boon for the company and is likely to take the EBITDA margins northward. Given the robust volume growth, which is being incrementally driven at the margin by short-term/spot LNG, this price hike significantly raises the likelihood of the EBITDA margins reverting to around Rs 5 per standard cubic metre levels in the near term. The company looks like an attractive candidate for one’s portfolio from a medium-term perspective.

Last Seven Days' Volume Table (No. of Shares)
DaysVolume
28-Feb-12 29685
29-Feb-12 166964
1-Mar-12 196227
2-Mar-12 79682
3-Mar-12 3418
5-Mar-12 365152
6-Mar-12 245000

[PAGE BREAK]

TORRENT PHARMACEUTICALS | BSE Code: 500420 | Volume: 142 | CMP: Rs 565

Torrent Pharma has 36 brands leading in their respective molecule segments, of which six feature in the list of India’s top 300 pharma brands. With new product launches, the company has been able to maintain its dominant position in the domestic Cardiovascular and Central Nervous System segments. In line with the industry trend, Torrent Pharma has maintained its tilt towards the chronic profile over the acute one. It has successfully increased its footprint in international markets, which contributed around 51 per cent to its total revenues in FY11. Brazil contributes majorly to its international division, with 27 successful drug launches there. The management has also taken corrective action in terms of addition and improvement in efficiency of its field force. Apart from the regular 25-30 drug launches in the domestic market every year, the company is planning to enter new therapeutic segments like oncology and infertility to widen its offerings. One can look at the scrip from a medium-term perspective.

Last Seven Days' Volume Table (No. of Shares)
DaysVolume
28-Feb-12 304
29-Feb-12 677
1-Mar-12 9426
2-Mar-12 3744
3-Mar-12 --
5-Mar-12 434
6-Mar-12 142

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Mindshare28-Mar, 2024

Penny Stocks28-Mar, 2024

Penny Stocks28-Mar, 2024

Penny Stocks28-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR